Impact of Time to Initiation of Postoperative Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy on the Prognosis of Locally Advanced Gastric Cancer: a Multi-center Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 524
- Locations
- 1
- Primary Endpoint
- 3-year all-caused mortality, 3-year Gastric-Cancer Specific Motality
Study Overview
Brief Summary
he present study retrospectively analyzed the clinicopathological data of 524 patients diagnosed with LAGC who underwent D2 radical gastrectomy after NACT between January 2010 and December 2021 at 2 centers. This study was conducted in accordance with the ethical principles outlined in the World Medical Association's Declaration of Helsinki. Informed consent was obtained from all patients and their legal guardians. All procedures were approved by the institutional review board.
Detailed Description
This is a retrospective, multicenter study.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 84 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •(1) Locally advanced gastric cancer with preoperative clinical staging of cT2-4NxM0 before neoadjuvant chemotherapy. (2) No history of other malignant tumors. (3) No evidence of distant metastasis or invasion of adjacent organs. (4) Underwent gastrectomy after receiving neoadjuvant chemotherapy.
Exclusion Criteria
- •(1) History of prior gastrectomy. (2) History of acute cardiovascular diseases (such as cerebral or coronary artery injuries) within the past three months. (3) Emergency surgery. (4) Did not undergo postoperative adjuvant chemotherapy. (5) Lack of specific information regarding chemotherapy regimens. (6) Loss to follow-up.
Outcomes
Primary Outcomes
3-year all-caused mortality, 3-year Gastric-Cancer Specific Motality
Time Frame: 3 years or 36 months.
Survival status at 3 years: survival, death, survival with tumor
Secondary Outcomes
No secondary outcomes reported
Investigators
Chang-Ming Huang, Prof.
M.D. FACS
Fujian Medical University